These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32210365)

  • 1. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Gridelli C; Ciuleanu T; Domine M; Szczesna A; Bover I; Cobo M; Kentepozidis N; Zarogoulidis K; Kalofonos C; Kazarnowisz A; Korozan M; de Las Penas R; Majem M; Chella A; Griesinger F; Bournakis E; Sadjadian P; Kotsakis A; Chinet T; Syrigos KN; Correale P; Gallou C; Jamet JM; Vetsika EK; Kosmatopoulos K; Georgoulias V;
    Br J Cancer; 2020 May; 122(10):1461-1466. PubMed ID: 32210365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
    Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001.
    Vetsika EK; Konsolakis G; Aggouraki D; Kotsakis A; Papadimitraki E; Christou S; Menez-Jamet J; Kosmatopoulos K; Georgoulias V; Mavroudis D
    Cancer Immunol Immunother; 2012 Feb; 61(2):157-168. PubMed ID: 21858533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
    Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
    Front Immunol; 2020; 11():572172. PubMed ID: 33324397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
    Giaccone G; Bazhenova LA; Nemunaitis J; Tan M; Juhász E; Ramlau R; van den Heuvel MM; Lal R; Kloecker GH; Eaton KD; Chu Q; Dunlop DJ; Jain M; Garon EB; Davis CS; Carrier E; Moses SC; Shawler DL; Fakhrai H
    Eur J Cancer; 2015 Nov; 51(16):2321-9. PubMed ID: 26283035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
    Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I; Kotsakis A; Papadimitraki E; Aggouraki D; Konsolakis G; Vagia A; Christophylakis C; Nikoloudi I; Magganas E; Galanis A; Cordopatis P; Kosmatopoulos K; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Jul; 25(19):2727-34. PubMed ID: 17602077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics.
    Georgoulias V; Douillard JY; Khayat D; Manegold C; Rosell R; Rossi A; Menez-Jamet J; Iché M; Kosmatopoulos K; Gridelli C
    Clin Lung Cancer; 2013 Jul; 14(4):461-5. PubMed ID: 23647738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study.
    Kotsakis A; Vetsika EK; Christou S; Hatzidaki D; Vardakis N; Aggouraki D; Konsolakis G; Georgoulias V; Christophyllakis Ch; Cordopatis P; Kosmatopoulos K; Mavroudis D
    Ann Oncol; 2012 Feb; 23(2):442-9. PubMed ID: 21873272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
    Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
    Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
    Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Cicènas S; Geater SL; Petrov P; Hotko Y; Hooper G; Xia F; Mudie N; Wu YL
    Lung Cancer; 2016 Dec; 102():30-37. PubMed ID: 27987585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
    Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA
    Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
    Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
    J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Kobayashi E; Kishi H; Muraguchi A; Kaneko S
    Cancer Lett; 2015 Aug; 364(2):98-105. PubMed ID: 25982205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.
    Adotévi O; Mollier K; Neuveut C; Dosset M; Ravel P; Fridman WH; Tartour E; Charneau P; Wain-Hobson S; Langlade-Demoyen P
    Blood; 2010 Apr; 115(15):3025-32. PubMed ID: 20130242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
    Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
    Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.